Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6209 and Fulvestrant in HR+/HER2- Solid Tumors
NCT07358377Phase 1Recruiting
- Sponsor
- Atridia Pty Ltd
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-6209 in breast cancer and solid tumor, sponsored by Atridia Pty Ltd. Primary endpoint: Adverse Events up to 1 year. Started May 2026; status: recruiting.
02
Drugs
HRS-6209
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT07358377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358377.